Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT ID: NCT03486873

This clinical trial, called MK-3475-587, is looking into the long-term safety and effectiveness of a treatment called pembrolizumab (also known as MK-3475) for patients with advanced tumors. If you...

Recruiting

Phase: PHASE3 Conditions: Solid Tumors, Hematologic Malignancies

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

NCT ID: NCT05949684

The ELEMENT-MDS clinical trial is studying how effective and safe a medication called Luspatercept is for treating anemia in adults with Myelodysplastic Syndromes (MDS) who are not receiving blood ...

Recruiting

Phase: PHASE3 Conditions: Myelodysplastic Syndromes

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT ID: NCT06140836

The TRIDENT-3 clinical trial is studying two medications, repotrectinib and crizotinib, to see how effective and safe they are for treating patients with a specific type of lung cancer called ROS1-...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT ID: NCT05020236

The MagnetisMM-5 clinical trial is studying a new treatment option for people with relapsed or refractory multiple myeloma, a type of blood cancer. Researchers want to see if a medication called el...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT ID: NCT06356129

This clinical trial is studying a new treatment for patients with a type of cancer called high-risk large B-cell lymphoma (LBCL). Researchers want to see if adding a medication called golcadomide t...

Recruiting

Phase: PHASE3 Conditions: Large B-cell Lymphoma

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT ID: NCT06456346

This clinical trial, called MK-3543-007, is studying a new medication called bomedemstat to see if it works better than hydroxyurea for treating people with a condition called Essential Thrombocyth...

Recruiting

Phase: PHASE3 Conditions: Essential Thrombocythemia

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

NCT ID: NCT06465186

This clinical trial is studying a new medicine called efinopegdutide to see if it can help people with a liver disease known as metabolic dysfunction-associated steatohepatitis (MASH), which is cau...

Recruiting

Phase: PHASE2 Conditions: NAFLD, Non-alcoholic Fatty Liver Disease +3 more

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT ID: NCT07063745

This clinical trial is studying a new treatment approach for people with a specific type of advanced lung cancer called metastatic non-small cell lung cancer (NSCLC) who have a particular genetic c...

Not yet recruiting

Phase: PHASE2 Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT ID: NCT06052059

This clinical trial is studying a new medication called tulisokibart (MK-7240) to see if it is effective and safe for people with moderately to severely active ulcerative colitis, a condition that ...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT ID: NCT06077760

This clinical trial is looking at a new treatment combination for patients with non-small cell lung cancer (NSCLC) who have had surgery to remove their cancer. The study compares the effects of a d...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT ID: NCT06152575

The MagnetisMM-32 clinical trial is studying a new medicine called elranatamab for people with multiple myeloma (MM), a type of blood cancer that has returned after previous treatments. The trial a...

Recruiting

Phase: PHASE3 Conditions: Multiple Myeloma

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT ID: NCT06430801

This clinical trial is studying a new medication called tulisokibart, which is being tested for its effectiveness and safety in treating people with moderate to severe Crohn's disease. Crohn's dise...

Recruiting

Phase: PHASE3 Conditions: Crohn's Disease

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

NCT ID: NCT05869955

This clinical trial is investigating a new treatment called CC-97540, which uses special immune cells (CAR T cells) designed to target a protein involved in certain autoimmune diseases. The goal of...

Recruiting

Phase: PHASE1 Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus +2 more

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT ID: NCT04224493

This clinical trial is testing a new treatment combination for adults with relapsed or refractory follicular lymphoma, a type of blood cancer that has returned or is resistant to previous therapies...

Recruiting

Phase: PHASE3 Conditions: Follicular Lymphoma, Refractory Follicular Lymphoma +1 more

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT ID: NCT05519085

This clinical trial is investigating a new treatment combination for patients with relapsed or refractory multiple myeloma (RRMM), which means their cancer has returned or did not respond to previo...

Recruiting

Phase: PHASE3 Conditions: Relapsed or Refractory Multiple Myeloma

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

NCT ID: NCT06911502

The GOLSEEK-4 trial is a clinical study designed to compare the effectiveness and safety of a new treatment called golcadomide combined with rituximab against the current best treatment options for...

Recruiting

Phase: PHASE3 Conditions: Follicular Lymphoma

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT ID: NCT06292013

The ACCLAIM-Lp(a) trial is studying a new treatment called lepodisiran to see if it can help reduce the risk of serious heart problems in adults who have high levels of a substance called lipoprote...

Recruiting

Phase: PHASE3 Conditions: Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT ID: NCT06890598

This clinical trial is studying a new treatment called olomorasib, which is being tested alongside standard treatments for patients with a specific type of lung cancer known as KRAS G12C-mutant non...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT ID: NCT06119581

This clinical trial is investigating whether a new drug called LY3537982, combined with standard cancer treatments like immunotherapy and chemotherapy, is more effective for patients with advanced ...

Recruiting

Phase: PHASE3 Conditions: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT ID: NCT03519945

The LUCENT 3 clinical trial is studying a medication called mirikizumab to see how effective and safe it is for treating people with moderately to severely active ulcerative colitis (UC) over a lon...

Recruiting

Phase: PHASE3 Conditions: Ulcerative Colitis

Main Menu

Clinical Trials in Pessac, Aquitaine

26 Active Trials Found in Pessac

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)